Biotechnology Industry Email List — 2,186,442+ Verified Contacts
Reach verified decision-makers across pharmaceutical biotech companies, agricultural biotech firms, contract research organizations, genomics companies, synthetic biology startups, bioprocessing technology vendors, and university research commercialization offices worldwide. Verified at 97% accuracy. Delivered within 24 hours.
Request Your Free Sample
50–100 verified contacts · 24hr delivery · No obligation
About the Biotechnology Industry
The global biotechnology industry represents one of the most scientifically dynamic, commercially significant, and rapidly growing sectors in the world economy. With a global market value exceeding $1.4 trillion and forecast compound annual growth rates of 13 to 15% through 2030, biotechnology encompasses the development and commercialization of biological systems and living organisms for applications spanning human healthcare, agricultural productivity, industrial chemical production, environmental remediation, and food and nutrition science. The sector is driven by continuous breakthroughs in genomics, proteomics, gene editing, mRNA technology, cell and gene therapy, synthetic biology, and artificial intelligence-powered drug discovery that are compressing the timeline from scientific insight to therapeutic or commercial product faster than at any previous point in the industry's history.
The pharmaceutical biotechnology segment — companies developing biologic drugs, vaccines, gene therapies, and cell therapies — is the largest and most commercially significant sub-sector of the global biotech industry. Companies like Amgen, Gilead Sciences, Regeneron Pharmaceuticals, BioNTech, Moderna, Vertex Pharmaceuticals, Biogen, and thousands of clinical-stage biotechs represent the core of the industry's R&D activity. These companies collectively employ tens of thousands of scientists, clinical development professionals, regulatory affairs specialists, business development executives, and commercial operations leaders who make significant purchasing decisions for laboratory equipment, research technology, clinical trial services, regulatory consulting, and bioprocessing infrastructure. Understanding who these decision-makers are and how to reach them directly is the central challenge for any vendor selling into the biotech R&D ecosystem.
The agricultural biotechnology sector — encompassing companies developing genetically engineered crops, biopesticides, biofertilizers, and precision fermentation products — represents another major segment of the biotechnology industry. Companies like Corteva Agriscience, Syngenta, BASF Agricultural Solutions, Bayer Crop Science, and a rapidly growing ecosystem of ag-biotech startups are developing next-generation biological products to address food security, climate resilience, and agricultural sustainability challenges. These companies are active buyers of research technology, bioinformatics platforms, field trial management systems, and regulatory advisory services. Industrial biotechnology — companies using biological systems to produce chemicals, materials, fuels, and food ingredients through fermentation and enzymatic processes — represents a third major segment with its own distinct technology and service procurement needs.
ELP Data's Biotechnology Industry email list gives you direct access to 2,186,442+ verified professionals across all these segments. Whether you are targeting pharmaceutical biotech R&D decision-makers, agricultural biotech procurement managers, contract research organization business development contacts, or genomics technology buyers, our database delivers the verified, current contact data you need to build meaningful pipeline in one of the world's most innovative and commercially dynamic sectors. Every contact is validated for email deliverability, job title accuracy, and company information currency before inclusion.
How Companies Use the Biotechnology Industry Email List
Laboratory equipment and instrumentation manufacturers — companies selling bioreactors, cell culture systems, chromatography equipment, centrifuges, mass spectrometers, next-generation sequencing instruments, flow cytometers, and analytical chemistry tools — represent the largest buyer category for the Biotechnology Industry email list. These manufacturers, which include global industry leaders like Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Sartorius, Cytiva, Agilent Technologies, Bio-Rad, Beckman Coulter, and hundreds of specialty instrument companies, need verified contact data for research scientists, laboratory directors, and process development VPs at biotech companies that are actively purchasing or evaluating laboratory infrastructure. Direct email access to these buyers enables manufacturers to reach procurement decision-makers at precisely the moments when research programs are expanding and capital equipment budgets are being committed.
Contract research organizations and contract manufacturing organizations — companies offering outsourced research, preclinical testing, clinical trial management, analytical testing, and biologic manufacturing services — represent one of the most active buyer categories for the Biotechnology Industry email list. The CRO and CDMO market exceeded $80 billion globally in 2024 and is growing rapidly as biotech companies increasingly outsource research and manufacturing activities to focus internal resources on core scientific innovation. CROs and CDMOs need verified access to VP of Business Development, Head of Operations, and Chief Scientific Officer contacts at clinical-stage and commercial-stage biotech companies that are evaluating outsourcing partnerships for current or upcoming programs. The decision to engage a CRO or CDMO is typically made 12 to 24 months before it becomes visible in public announcements — meaning early direct outreach to the right contacts is the key to winning these partnerships before competitors.
Biotechnology software vendors — companies selling electronic laboratory notebook platforms, laboratory information management systems, clinical trial management systems, regulatory submission software, bioinformatics tools, AI-powered drug discovery platforms, and quality management systems — use the Biotechnology Industry email list to reach Chief Scientific Officers, Director of Laboratory Operations, VP of IT, and Regulatory Affairs Directors at biotech companies evaluating software investments. The digitization of biotech R&D — driven by FDA and EMA mandates for electronic records, the adoption of AI in drug discovery, and the need for integrated data management across large research programs — is generating sustained software procurement activity at biotech companies of all sizes and stages.
Biotechnology-focused investment banks, venture capital firms tracking portfolio company development, licensing and partnership teams at large pharmaceutical companies, and management consultancies serving the life sciences sector use the Biotechnology Industry email list to reach biotech founders, CEOs, Chief Business Officers, and Head of Licensing contacts at innovative early and mid-stage companies. For pharma companies actively building external innovation portfolios through licensing, co-development, and acquisition, access to verified CEO and business development contacts at clinical-stage biotechs is operationally critical for efficient pipeline sourcing. For VC firms, verified contact data for founders and senior scientists at pre-funding and early-stage companies enables proactive deal sourcing before companies become visible through traditional deal flow channels.
Industry Segments Covered
Our Biotechnology Industry email list covers every major segment within the global biotech ecosystem. Filter by segment, therapeutic area, or company stage to build precisely targeted contact lists.
Pharmaceutical Biotech
R&D directors, clinical development VPs, CSOs, and regulatory affairs leaders at clinical-stage and commercial-stage biopharma companies in every major therapeutic area.
Genomics & Diagnostics
Bioinformatics directors, genomics laboratory heads, diagnostics development managers, and sequencing technology buyers at genomics and molecular diagnostics companies.
Agricultural Biotech
Chief Science Officers, R&D directors, regulatory affairs managers, and business development leads at ag-biotech companies developing novel seed, crop protection, and biofertilizer technologies.
Industrial Biotech
Fermentation process directors, industrial enzyme development managers, and scale-up engineering leads at companies using biological systems for chemical, materials, and fuel production.
Contract Research (CRO)
VP Business Development, Head of Scientific Services, clinical program managers, and analytical laboratory directors at contract research and contract manufacturing organizations.
Bioprocessing & Manufacturing
VP Manufacturing, process development directors, bioprocessing engineers, and quality assurance VPs overseeing biological manufacturing scale-up and commercial production.
Synthetic Biology & Cell Therapy
Founders, CSOs, and R&D directors at synthetic biology platforms and cell and gene therapy companies working on next-generation biological engineering applications.
Biotech Investment & Licensing
Life sciences VCs, pharma business development heads, licensing directors, and strategic alliance managers at firms actively building biotech investment and partnership portfolios.
Biotechnology Industry News
Key developments shaping the global biotechnology sector and driving investment, research activity, and commercial procurement across the industry.
Global Biotech Investment Rebounds to $42 Billion in 2024 as AI-Driven Drug Discovery Attracts Record Capital
Global biotechnology venture capital investment rebounded strongly to $42 billion in 2024, driven by record investor interest in AI-powered drug discovery platforms, cell and gene therapy companies, and GLP-1 adjacent metabolic disease biotech. Leading AI drug discovery companies including Recursion Pharmaceuticals, Insilico Medicine, and Exscientia have attracted hundreds of millions in new funding as major pharmaceutical companies race to build AI-driven R&D capabilities. The investment surge is creating significant procurement activity for laboratory infrastructure, computational biology platforms, and clinical development services across the sector.
mRNA Platform Technology Expands Beyond Vaccines Into Oncology, Rare Disease, and Autoimmune Applications
Following the extraordinary success of mRNA COVID-19 vaccines, BioNTech, Moderna, and a growing cohort of mRNA technology companies are advancing mRNA therapeutics programs in oncology, personalized cancer vaccines, rare disease, and autoimmune conditions through clinical development. The expansion of mRNA applications is driving significant demand for specialized lipid nanoparticle delivery technology, mRNA synthesis and purification equipment, cold chain logistics, and regulatory expertise in this rapidly evolving field. Companies with technology or services relevant to the mRNA ecosystem are seeing accelerated commercial opportunity as the platform matures beyond its vaccine origins.
FDA Accelerates Approval Pathways for Cell and Gene Therapies as Pipeline Reaches Record Scale
The US Food and Drug Administration reported a record pipeline of over 4,000 cell and gene therapy clinical trials currently active or under IND review — a number that has tripled since 2020. The FDA has announced additional accelerated approval pathway enhancements specifically designed to maintain regulatory review capacity proportionate to the surging pipeline. The boom in cell and gene therapy programs is generating significant demand for specialized GMP manufacturing facilities, viral vector production technology, cell culture systems, cold chain logistics, and the highly specialized regulatory expertise required for these complex biological product submissions.
Geographic Coverage Breakdown
Strong coverage across the world's major biotechnology hubs — from the Boston–Cambridge corridor and Bay Area to London, Basel, Copenhagen, Singapore, and Tokyo.
| Region | Contacts | Share | Coverage |
|---|---|---|---|
| 🇺🇸 North America (USA, Canada) | 1,093,220 | 50% | |
| 🇬🇧 Europe (UK, Germany, Switzerland, Denmark, France) | 524,746 | 24% | |
| 🌏 Asia Pacific (Japan, China, South Korea, Australia, Singapore) | 393,560 | 18% | |
| 🌍 Middle East & Israel (Israel, UAE) | 131,186 | 6% | |
| 🌎 Rest of World (Latin America, India, Others) | 43,730 | 2% |
Job Title Breakdown
Filter by specific job titles to reach exactly the right biotech decision-makers, scientific buyers, and business development contacts for your campaign.
| Job Title | Contacts | % of List | Distribution |
|---|---|---|---|
| Chief Scientific Officer / VP R&D | 349,830 | 16% | |
| CEO / President / Founder | 218,644 | 10% | |
| Director of Clinical Development / CMO | 262,372 | 12% | |
| Director of Regulatory Affairs / VP Regulatory | 196,780 | 9% | |
| VP Business Development / Head of Licensing | 218,644 | 10% | |
| VP Manufacturing / Process Development Director | 174,916 | 8% | |
| Director of Bioinformatics / Computational Biology | 131,186 | 6% | |
| VP Quality Assurance / Quality Director | 109,322 | 5% | |
| Director of Laboratory Operations | 152,050 | 7% | |
| CTO / Head of Technology | 131,186 | 6% | |
| Senior Scientist / Principal Scientist | 241,512 | 11% |
Why Biotechnology Industry Contacts Are High-Value B2B Targets
Biotech decision-makers control significant research and operational budgets and make high-value technology and service procurement decisions that directly determine the pace and success of drug development programs. Here is why vendors prioritize direct access to biotech contacts.
Biotech R&D Budgets Are Large, Growing, and Concentrated in High-Value Decisions
Clinical-stage biotech companies typically spend between $50 million and $500 million per year on research and development — with a significant portion allocated to laboratory equipment, outsourced research services, technology platforms, regulatory consulting, and clinical trial operations. Commercial-stage biotech companies have even larger operational budgets, adding manufacturing, quality, pharmacovigilance, and commercial operations spending to their R&D investment. A single capital equipment purchase decision — a new bioreactor system, a high-throughput screening platform, a mass spectrometry instrument — can be worth hundreds of thousands to millions of dollars. Direct email access to the scientific and operational decision-makers who drive these purchases is the most efficient path to initiating the conversations that lead to these high-value relationships.
Rapidly Growing Sector Creates Continuous New Buyer Emergence
The global biotechnology industry adds hundreds of new companies and thousands of new decision-makers every year through new company formation, significant funding rounds that enable expansion, clinical trial initiations that require new CRO and CDMO partnerships, and technology platform buildouts that create new equipment and software procurement needs. This continuous emergence of new buyers means that a contact list that was current twelve months ago may miss a significant proportion of the most commercially attractive new prospects in the sector. ELP Data's quarterly database refresh process is specifically designed to capture these newly emerged decision-makers — ensuring that your campaigns reach not just established biotech companies but also the high-growth, well-funded clinical-stage companies that are often the most eager and responsive buyers of the technology and services they need to advance their programs.
Outsourcing Trend Creates Urgent, High-Value CRO and CDMO Procurement
The structural shift toward outsourced research, manufacturing, and development in the biotech industry has created a massive market for contract research organizations, contract development and manufacturing organizations, specialty testing laboratories, clinical trial site networks, and specialized research service providers. Biotech companies without the scale or expertise to build all research and manufacturing capabilities in-house make outsourcing decisions worth millions of dollars for each program they advance through development. These outsourcing decisions are made by VP of Operations, Head of Business Development, and CMO contacts who are simultaneously managing complex multi-partner ecosystems and constantly evaluating new service provider relationships. Direct, credentialed outreach to these contacts at the right stage of their program timelines is the key to winning outsourcing partnerships before competitors establish incumbent relationships.
AI and Digital Transformation Drive New Technology Adoption Cycles Across Biotech
The application of artificial intelligence to drug discovery, clinical trial design, biomarker identification, patient selection, and manufacturing process optimization is creating an entirely new technology adoption cycle in the biotech sector that is generating significant new procurement activity from companies who had not historically been major software buyers. Biotech companies investing in AI-powered R&D platforms, electronic laboratory notebooks, laboratory information management systems, and integrated data management infrastructure are making first-time purchases of enterprise software systems — creating commercial opportunities for technology vendors who can reach Chief Scientific Officers, Director of Laboratory Operations, and VP of IT contacts at the biotech companies that are at the early stages of their digital transformation journey.
What ELP Data Provides in Every Record
Each contact in the Biotechnology Industry email list includes comprehensive professional and firmographic fields ready for your CRM, marketing automation platform, or outbound sales tool.
- Full Name
- Job Title
- Direct Email Address
- Direct Phone Number
- LinkedIn Profile URL
- Company Name
- Company Website
- Company Headcount
- Funding Stage / Revenue
- Biotech Sub-sector
- Country & City
- Seniority Level
- Department
- Therapeutic Area / Focus
- Data Verified Date
Sample Data Preview
The table below shows the structure and quality of records in the Biotechnology Industry email list. Email addresses are blurred for privacy — full data is available upon request.
| Name | Title | Company | Phone | Country | |
|---|---|---|---|---|---|
| Dr. Sarah Goldstein | Chief Scientific Officer | Vertex Biosciences Inc | s.gold●●●●@vtx●●●●.com | +1 (617) 4●●-●●●● | USA |
| Dr. Lars Bjornsen | VP Clinical Development | Zealand Pharma A/S | l.bjor●●●●@zea●●●●.dk | +45 39 ●●●-●●●● | Denmark |
| Yuki Taniguchi | Director of Regulatory Affairs | Chugai Pharmaceutical | y.tani●●●●@chu●●●●.co.jp | +81 3 ●●●●-●●●● | Japan |
| Dr. Priya Venkatesh | Head of Bioinformatics | Strand Life Sciences | p.venk●●●●@str●●●●.in | +91 80 ●●●●-●●●● | India |
| Marcus Holloway | VP Business Development | Evotec SE | m.holl●●●●@evo●●●●.de | +49 40 ●●●-●●●● | Germany |
Frequently Asked Questions
What Our Clients Say
Laboratory equipment manufacturers, CROs, biotech software vendors, and life sciences service providers share their results using ELP Data for biotechnology sector outreach.
“ELP Data's Biotechnology Industry email list gave us verified access to VP of Process Development and Director of Manufacturing contacts at clinical-stage and commercial-stage biotech companies that we had previously struggled to reach. Our first campaign generated 14 qualified conversations with companies actively evaluating bioreactor systems and process development tools. The data accuracy was exceptional and deliverability was consistently above 96% across all segments. We have made ELP Data our primary source for biotech sector outreach.”
“We needed to reach VP of Business Development and Head of Licensing contacts at clinical-stage biotech companies that might be looking for CRO partnerships for Phase II and Phase III trials. ELP Data built us a custom list filtered by company stage, therapeutic area — oncology and rare disease primarily — and geography across the US and Europe. The list quality was outstanding. Our outreach response rate was more than double what we had achieved with previous data providers.”
“Reaching Director of Laboratory Operations and Chief Scientific Officer contacts at pre-commercial biotech companies is genuinely difficult with generic business databases because company names and decision-maker details change rapidly in this sector. ELP Data's quarterly refresh process made a real difference — the contacts we received were current and accurate. Our campaign open rates exceeded 27% and we saw measurable inbound interest from the biotech segment within weeks of launching. Extremely satisfied with the quality.”
“We sell next-generation sequencing instruments and genomics data analysis software to biotech R&D teams. Reaching the right Director of Bioinformatics and VP of R&D contacts at companies working in our target therapeutic areas required extremely precise segmentation. ELP Data provided exactly that — a custom list filtered by therapeutic area, company stage, and specific job titles with a data quality level we had not seen from other providers. The list directly supported three major new partnerships in the first quarter after purchase.”
Related Email Lists & Databases
Explore related industry and role-based email lists to expand your reach across adjacent life sciences markets and decision-maker types.